Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MINASTRIN 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MINASTRIN 24 FE.
GENCEPT 10/11-28 vs MINASTRIN 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-27 hours. Clinical context: Steady-state achieved within 5-10 days; half-life supports once-daily dosing.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Urine (primarily as glucuronide conjugates; ethinyl estradiol and norethindrone metabolites) and feces. Approximately 40% of norethindrone metabolites are excreted in urine and 60% in feces. Ethinyl estradiol is excreted as glucuronide and sulfate conjugates in urine (40%) and feces (60%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive